Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis
Amir M. Mohareb, Bonolo Phinius, Motswedi Anderson, Shahin Lockman, Julie Bottero, George A. Yendewa, Arthur Y. Kim, Anders Boyd · 2026
Read Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis by Amir M. Mohareb, Bonolo Phinius, Motswedi Anderson, Shahin Lockman, Julie Bottero, George A. Yendewa, Arthur Y. Kim, Anders Boyd (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427494.txt.
Description
Amir M. Mohareb and colleagues pooled hepatitis B outcomes after stopping tenofovir in people with HIV in a 2026 systematic review and meta-analysis. Tenofovir-containing regimens suppress both viruses, and tenofovir-free HIV regimens are spreading, raising concern about hepatitis B flare or new infection. Searches of Medline, Embase, Google Scholar, and Cochrane covered January 2006 to February 2026 and separated active, resolved, and susceptible hepatitis B groups.
A random effects model combined reactivation and infection risks across studies for each immune category. Clinicians switching regimens gain quantified risk estimates to plan monitoring and vaccination. Pills that drop one virus but not its twin can let the twin wake and flare, so a swap of drugs must be made with both germs in mind at once.
Catalog record
| CREATOR | Amir M. Mohareb, Bonolo Phinius, Motswedi Anderson, Shahin Lockman, Julie Bottero, George A. Yendewa, Arthur Y. Kim, Anders Boyd |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54579 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |